Isovaleric acidemia: New aspects of genetic and phenotypic heterogeneity
- 6 April 2006
- journal article
- review article
- Published by Wiley in Seminars in Medical Genetics, Part C of the American Journal of Medical Genetics
- Vol. 142C (2), 95-103
- https://doi.org/10.1002/ajmg.c.30089
Abstract
Isovaleric acidemia (IVA) is an autosomal recessive inborn error of leucine metabolism caused by a deficiency of the mitochondrial enzyme isovaleryl‐CoA dehydrogenase (IVD) resulting in the accumulation of derivatives of isovaleryl‐CoA. It was the first organic acidemia recognized in humans and can cause significant morbidity and mortality. Early diagnosis and treatment with a protein restricted diet and supplementation with carnitine and glycine are effective in promoting normal development in severely affected individuals. Both intra‐ and interfamilial variability have been recognized. Initially, two phenotypes with either an acute neonatal or a chronic intermittent presentation were described. More recently, a third group of individuals with mild biochemical abnormalities who can be asymptomatic have been identified through newborn screening of blood spots by tandem mass spectrometry. IVD is a flavoenzyme that catalyzes the conversion of isovaleryl‐CoA to 3‐methylcrotonyl‐CoA and transfers electrons to the electron transfer flavoprotein. Human IVD has been purified from tissue and recombinant sources and its biochemical and physical properties have been extensively studied. Molecular analysis of the IVD gene from patients with IVA has allowed characterization of different types of mutations in this gene. One missense mutation, 932C>T (A282V), is particularly common in patients identified through newborn screening with mild metabolite elevations and who have remained asymptomatic to date. This mutation leads to a partially active enzyme with altered catalytic properties; however, its effects on clinical outcome and the necessity of therapy are still unknown. A better understanding of the heterogeneity of this disease and the relevance of genotype/phenotype correlations to clinical management of patients are among the challenges remaining in the study of this disorder in the coming years.Keywords
This publication has 95 references indexed in Scilit:
- Isovaleric acidemia: Response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapyThe Journal of Pediatrics, 1996
- Lessons from the late diagnosis of isovaleric acidemia in a five-year-old boyThe Journal of Pediatrics, 1996
- Comparative frequency and severity of hypoglycemia in selected organic acidemias, branched chain amino acidemia, and disorders of fructose metabolismBrain & Development, 1994
- Pancreatitis in patients with organic acidemiasThe Journal of Pediatrics, 1994
- Isovaleric acidemia: Medical and neurodevelopmental effects of long-term therapyThe Journal of Pediatrics, 1988
- Endogenous catabolism as source of toxic metabolites in isovaleric acidemiaThe Journal of Pediatrics, 1987
- Maternal isovaleric acidemiaThe Journal of Pediatrics, 1984
- Isovaleric Acidemia: Use of Glycine Therapy in NeonatesThe New England Journal of Medicine, 1978
- Glycine therapy in isovaleric acidemiaThe Journal of Pediatrics, 1978
- Identification of β-hydroxyisovaleric acid in the urine of a patient with isovaleric acidemiaBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1968